All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
Topline results obtained from a phase I dose escalation trial (NCT04588922) show that primary and secondary endpoints in safety, clinical activity, pharmacokinetics, and pharmacodynamics were met in patients with relapsed/refractory (R/R) lymphomas.1 These results indicate that SLS009 (formerly GFH009) may be a safe and efficacious treatment option for this patient population.1
A total of 52 R/R patients with lymphoma were enrolled and 34 patients were evaluable for efficacy. In this population:
No patients had unexpected toxicities and the drug was well tolerated, with no drug-related deaths reported at any dose level.
The topline data from this phase I dose-escalation trial have led to a phase II clinical study. This study will assess SLS009 in patients with peripheral T-cell lymphoma, further elucidating the potential of this treatment for those with hematologic malignancies who have exhausted previous treatment options.1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox